Press

As 2025 comes to a close, we reflect on a year of growth and engagement that underscores the FTD Disorders Registry’s role in advancing research and amplifying the voices of those impacted by FTD.

The FTD Disorders Registry was featured at CTAD in San Diego, where a poster presented by Dr. Shana Dodge highlighted how the Registry is helping accelerate clinical trial recruitment in frontotemporal degeneration.

353 people responded, sharing insights on the physical challenges that can come with FTD.

Every biosample holds valuable information that brings us closer to earlier diagnosis and effective treatments for FTD.

About 33% reported that they are actively exploring care options …

The Fall Research Roundup highlights new studies now enrolling people living with FTD, care partners, and biological family members.

Registry data is helping to bridge the gap between the FTD and ALS research communities and to accelerate recruitment for future clinical trials.

Registry data reveal which FTD subtypes and genes have the highest representation of research-ready participants, helping scientists design stronger, more focused studies.

Alector has announced topline results from its Phase 3 INFRONT-3 trial of latozinemab for FTD-GRN.

Life with FTD is about so much more than medical symptoms. To better understand the impact of FTD disorders, our September Quick Question asked …